

| Catalog No. | HS856086 |
|---|---|
| Description |
Sonelokimab (HS856086) is a research-grade recombinant antibody targeting CTLA-8. Produced in mammalian cells with native-like glycosylation.
Highlights
|
| Species reactivity | Human |
| Applications | ELISA, Bioactivity: FACS, Functional assay, Research in vivo |
| Host species | Human |
| Isotype | VH-VH'-VH |
| Expression system | Mammalian cells |
| Clonality | Monoclonal |
| Target | CTLA-8, Cytotoxic T-lymphocyte-associated antigen 8, IL17, IL-17A, IL17A, CTLA8, IL-17, Interleukin-17A, IL17F, Interleukin-17F, IL-17F, Cytokine ML-1, ALB, Albumin |
| Endotoxin level | < 10 EU/mg |
| Purity | >95% purity as determined by SDS-PAGE. |
| Purification | Purified by Nickel column. |
| Accession | Q16552 & Q96PD4 & P02768 |
| Form | Liquid |
| Storage buffer | 30 mM Histidine, pH5.8, 10% sucrose, 0.02% Tween80 Please refer to the specific buffer information in the hardcopy of datasheet or the lot-specific COA. |
| Stability and Storage | Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt. |
| Alternate Names | Bispecific, Trivalent, M-1095, MSB-0010841, 1414386-05-2 |
| Background | Sonelokimab (ALX 0761) is a trivalent bispecific nanobody composed of camel derived humanized IL-17F antibodies, IL-17A/F antibodies, and serum albumin VHH antibodies. Sonelokimab can prolong the plasma half-life by binding to human serum albumin. Sonelokimab can be used for research on rheumatoid arthritis and psoriasis. |
| Note | For research use only. Not suitable for clinical or therapeutic use. |

SDS-PAGE for Research Grade Sonelokimab
Contact us for custom quotes, bulk requests and any other issues.
Mail: support@abinScience.com


+86-27-65523339
Building C, No. 666, Shen Dun Si Lu, Wuhan, 430206, China
中文
English
한국어
日本語
Español
Français
Русский